<DOC>
	<DOCNO>NCT00031850</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . The use raloxifene goserelin may effective prevent breast cancer . PURPOSE : Randomized pilot study study effectiveness combine raloxifene goserelin prevent breast cancer woman family history breast cancer .</brief_summary>
	<brief_title>Raloxifene Goserelin Preventing Breast Cancer Women With Family History Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare feasibility raloxifene goserelin versus medical intervention woman high genetic risk develop breast cancer . - Compare incidence adverse effect patient treat regimen . - Compare effect regimens bone density , biochemical marker bone turnover , lipid profile patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center . Patients randomize one two treatment arm . - Arm I : Patients receive goserelin subcutaneously every month oral raloxifene daily 6-12 month . - Arm II : Patients screen breast cancer every 6 month . In arm , patient undergo annual mammogram . Quality life assess baseline 1 , 3 , 6 , 12 month . Patients follow 5 year . PROJECTED ACCRUAL : A total 150 patient ( 75 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : High genetic risk develop breast cancer define one following : BRCA1 BRCA2 germline mutation Firstdegree relative know BRCA1 BRCA2 mutation carrier Family 4 relative diagnose female male breast cancer ovarian cancer age 60 Two firstdegree relative diagnose breast cancer age 40 p53 germline mutation ( classical LiFraumeni syndrome ( LFS ) ) Firstdegree relative carrier family classical LFS Risk equivalent confirm clinical geneticist No evidence breast cancer mammography Suspicious lesion must confirm nonmalignant No prior breast cancer No prior prophylactic mastectomy No plan alternative prevention measure within next 12 month Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 30 45 Sex : Female Menopausal status : Premenopausal ( folliclestimulating hormone premenopausal range menstruate ) Performance status : Not specify Life expectancy : More 10 year ( exclude breast cancer risk ) Hematopoietic : Not specify Hepatic : Adequate liver function Renal : Adequate renal function Cardiovascular : No prior deep vein thrombosis Pulmonary : No prior pulmonary embolism Other : Not pregnant Fertile patient must use effective nonhormonal contraception No psychological disorder would preclude study compliance No prior malignancy within past 5 year except curatively treat nonmelanoma skin cancer cervical cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : No concurrent hormonal therapy ( e.g. , oral contraception hormone replacement therapy ) Radiotherapy : Not specify Surgery : See Disease Characteristics Other : At least 30 day 5 halflives since prior investigational drug No concurrent anticoagulant</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>breast cancer</keyword>
</DOC>